Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
Details for Australian Patent Application No. 2001264612 (hide)
International Classifications
Event Publications
4 November 2004 Change of Name(s) of Applicant(s), Section 104
IDEC Pharmaceuticals Corporation The name of the applicant has been changed to Biogen Idec Inc.
22 February 2007 Application Accepted
Published as AU-B-2001264612
28 June 2007 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 21 May 2007. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000
4 October 2007 Standard Patent Sealed
22 November 2007 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 21 May 2007
3 June 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser